ARTICLE | Finance
More NASH cash
Why investors are backing Cirius’ next-generation insulin sensitizer in NASH
April 14, 2017 8:04 PM UTC
Investors are hoping a $40 million A-2 round can help Cirius Therapeutics Inc. deliver the first clinical data in non-alcoholic steatohepatitis (NASH) showing a second-generation insulin sensitizer is not only efficacious, but also avoids the safety issues of first-generation sensitizers.
Frazier Healthcare Partners and Novo A/S led last week’s round, with participation by fellow new investors Adams Street Partners and Renaissance Venture Capital Fund and existing investor Hopen Life Science Ventures. ...
BCIQ Company Profiles